Retreatment with sofosbuvir plus grazoprevir plus elbasvir plus ribavirin of patients with Hepatitis C virus Genotype 1 or 4 with RASs at failure of a sofosbuvir plus ledipasvir or plus daclatasvir or plus simeprevir regimen (ANRS HC34 REVENGE study)

著录项

• 来源
  《Fundamental & clinical pharmacology.》 |2017年第1期|共1页
• 作者

  Laforest C.; Fougerou-Leurent C.; Pawlotsky J. M.; Hezode C.; Pol S.; Renault A.; Alric L.; Larrey D.; Metivier S.; Tran A.; Jezequel C.; Samuel D.; Zoulim F.; Pailhe A.; Gibowski S.; Bourliere M.; Bellissant E.; De Ledinghen V.;

  展开▼
• 作者单位

  Pontchaillou Hosp Pharmacol Unit Rennes France;

  Pontchaillou Hosp Pharmacol Unit Rennes France;

  Henri Mondor Hosp Dept Virol Creteil France;

  Henri Mondor Hosp Hepatol Unit Creteil France;

  Cochin Hosp Hepatol Unit Paris France;

  INSERM CIC 1414 Rennes France;

  Purpan Hosp Digest Dept Toulouse France;

  St Eloi Hosp Hepatol Unit Montpellier France;

  Purpan Hosp Hepatol Unit Toulouse France;

  Archet Hosp Hepatol Unit Nice France;

  Pontchaillou Hosp Liver Dis Unit Rennes France;

  Hop Paul Brousse Ctr Hepatobiliaire Villejuif France;

  Croix Rousse Hosp Hepatol Unit Lyon France;

  ANRS France REch Nord&

  Sud Sida Hiv Hepatites Paris France;

  ANRS France REch Nord&

  Sud Sida Hiv Hepatites Paris France;

  St Joseph Hosp Hepatol Unit Marseille France;

  Pontchaillou Hosp Pharmacol Unit Rennes France;

  Haut Leveque Hosp Hepatol Unit Bordeaux France;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类 药理学;
• 关键词